NIH Director's Blog: Drug Development

MARCH 18, 2021

He uses these fundamental insights to guide the design of vaccines and therapeutics, including promising monoclonal antibodies. He uses these fundamental insights to guide the design of vaccines and therapeutics, including promising monoclonal antibodies. Despite carrying all of these viruses, bats rarely show symptoms of being sick.

Virus 52

Virus Immune Response Clinical Trials Vaccine 52

PLOS: DNA Science

JULY 27, 2023

That information led, thanks to vaccine shelved from the first SARS circa 2003, to the rapid development and deployment of mRNA vaccines against the new infectious disease. The fear is that a variant of the deadly virus might emerge that infects people, and, worst-case-scenario, passes from person to person.

Disease 92

Disease DNA Virus RNA 92

NIH Director's Blog: Drug Development

MAY 21, 2020

B38 blocks SARS-CoV-2 from binding to the ACE2 receptor (light pink) of a human cell, ACE2 is what the virus uses to infect cells. Because of these and other factors, many experts think antibody-based therapies may offer one of the best near-term options for developing safe, effective treatments for COVID-19. In the U.S.

Virus 52

Virus Vaccine Laboratories Small Molecule 52

The Pharma Data

DECEMBER 23, 2020

Eligible patients enrolled in the trial receive treatment with AIM’s flagship pipeline drug Ampligen. All study subjects will receive the same Ampligen treatments. In addition, many survivors of the first SARS-CoV-1 epidemic in 2003 continued to report classic chronic fatigue-like symptoms after recovering from the acute illness.

Clinical Trials 52

Clinical Trials Trials Virus International 52

The Pharma Data

FEBRUARY 25, 2021

FDA ACCEPTS FOR PRIORITY REVIEW PFIZER’S APPLICATION FOR TICOVAC (TICK-BORNE ENCEPHALITIS VACCINE). If approved, the vaccine may help reduce the risk of TBE for people traveling to endemic areas, potentially including military personnel serving in these locations. 1,2 If approved, TicoVac would be the first vaccine in the U.S.

FDA 52

FDA Vaccine Virus Clinical Trials 52

Codon

AUGUST 27, 2024

While reading all the sequences present in a sample, researchers want to find any that are out of place, such as those that belong to a never-before-seen virus. In 2003, the DHS launched the BioWatch program after five people died and twenty fell ill from touching envelopes laced with anthrax spores.

DNA 84

DNA Hospitals Laboratories Virus 84

The Pharma Data

APRIL 25, 2021

Nirsevimab demonstrate d protect ion against respiratory syncytial virus disease in healthy infants in Phase 3 trial. Respiratory Syncytial Virus (RSV) is the leading cause of hospitalization in all infants. 1 – 5. RSV is the most common cause of LRTI and the leading cause of hospitalizations in all infants.

Virus 40

Virus Trials Disease Hospitals 40